drugset / Trial / NCT01037699

Luteinizing Hormone (LH) Supplementation in Gonadotropin-releasing Hormone (GnRH) Antagonist Cycles

NCT01037699

RandomizedParallel-groupOpen-labelTreatment

Summary

To analyse the impact on cycle outcome of LH supplementation in ovarian stimulation controlled with a GnRH antagonist in two ages groups: patients upto 35 years old, and patients aged between 36 and 39 years old.

Timeline

Start
2005-01
Primary completion
2008-03
Completion
2008-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator Follicle Stimulating Hormone Protein / enzyme biologic 150 iu
Comparator Follicle Stimulating Hormone Protein / enzyme biologic 225 iu
Comparator Follicle Stimulating Hormone Protein / enzyme biologic 300 iu
Subject Luteinizing Hormone Protein / enzyme biologic 75 iu

Indications

No indication recorded.